Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Symbol: 
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
05/23/20245:07PMEdgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:KNKnowles Corporation
05/23/20245:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MORNMorningstar Inc
05/23/20245:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
05/23/20245:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:SERSerina Therapeutics Inc
05/23/20245:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LMFALM Funding America Inc
05/23/20245:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XELXcel Energy Inc
05/23/20245:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PODDInsulet Corporation
05/23/20245:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMRNBioMarin Pharmaceutical Inc
05/23/20245:06PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BECNBeacon Roofing Supply Inc
05/23/20245:06PMEdgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NYSE:GS-JGoldman Sachs Group Inc
05/23/20245:05PMEdgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:HBIHanesbrands Inc
05/23/20245:05PMEdgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:NCNOnCino Inc
05/23/20245:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:CRMSalesforce Inc
05/23/20245:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PODDInsulet Corporation
05/23/20245:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRVAPrivia Health Group Inc
05/23/20245:05PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TCPCBlackRock TCP Capital Corporation
05/23/20245:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOOKHOOKIPA Pharma Inc
05/23/20245:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
05/23/20245:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EVAXEvaxion Biotech AS
05/23/20245:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRVAPrivia Health Group Inc
05/23/20245:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XELXcel Energy Inc
05/23/20245:05PMBusiness WireAulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
05/23/20245:05PMGlobeNewswire Inc.Elcora Announces Share ConsolidationTSXV:ERAElcora Advanced Materials Corp
05/23/20245:05PMGlobeNewswire Inc.Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024NASDAQ:AFMDAffimed NV
05/23/20245:05PMBusiness WireBristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research PlatformsNYSE:BMYBristol Myers Squibb Co
05/23/20245:05PMPR Newswire (US)EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
05/23/20245:05PMPR Newswire (US)Landmark Study from Mercy BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and Ultrasound for Ovarian Cancer Screening
05/23/20245:05PMPR Newswire (US)IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
05/23/20245:05PMPR Newswire (US)ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024TSX:ATDAlimentation Couche Tard Inc
05/23/20245:05PMPR Newswire (Canada)ALIMENTATION COUCHE-TARD TO RELEASE RESULTS FOR ITS FOURTH QUARTER AND FISCAL YEAR 2024 ON JUNE 25, 2024TSX:ATDAlimentation Couche Tard Inc